Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Camino Huerga"'
Publikováno v:
British journal of clinical pharmacology. 88(3)
Aims The pharmacokinetic (PK) similarity between MB02, a proposed bevacizumab biosimilar, and reference bevacizumab approved from the USA (US-bevacizumab) and European Union (EU-bevacizumab) was evaluated. Safety and immunogenicity were also assessed
Autor:
Susana Millan, Amalia Florez, Camino Huerga, Igor Bondarenko, Marta Abad, Yaroslav Shparyk, Felicitas Bullo, Alexandra Paravisini
Publikováno v:
Journal of Clinical Oncology. 37:e20731-e20731
e20731 Background: MB02 is a bevacizumab biosimilar developed to stringent guidelines, including non-clinical and preclinical investigations and a clinical trial as first-line treatment in metastatic colorectal cancer (Romera A et al. Lancet Gastroen
Autor:
Pradeep Shah, Igor Bondarenko, Vikas Ostwal, Susana Millan, Sajeed Abdul Rahuman, Fabio Franke, Francisco Javier Fernandez, Yaroslav Shparyk, Camino Huerga, Kathia Cristina Abdalla, Alexandra Paravisini, Suresh Sudalaiandi, Giovanni M. Bariani, Sulabhchandra Bhamare, Yuriy Vinnyk, Antonio Cubillo, Felipe Melo Cruz, Alvaro Romera, Enrique Roca
Publikováno v:
Journal of Clinical Oncology. 35:e14065-e14065
e14065 Background: BEVZ92 has being developed as a proposed biosimilar approved reference medicine product (RMP). BEVZ92 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to RMP. The aim of thi